Evidence-based guideline for prevention, assessment, and management of oral and GI mucositis in cancer patients receiving chemotherapy, radiation, and stem cell transplantation.
A comprehensive, evidence-based clinical guideline for the prevention, assessment, and management of oral and gastrointestinal mucositis in adult oncology patients. This resource synthesizes recommendations from major international professional societies, systematic reviews, and expert panels in supportive cancer care to provide a single integrated reference for oncologists, radiation oncologists, oncology dentists, oncology nurses, dietitians, and advanced practice providers who care for patients at risk for mucosal injury from cytotoxic therapy.1 2 3 4 5 6 7
Mucositis — the inflammatory and ulcerative breakdown of the mucosal lining of the oral cavity and gastrointestinal tract — is among the most common, debilitating, and dose-limiting toxicities of cancer treatment. Oral mucositis occurs in approximately 40% of patients receiving standard-dose chemotherapy, 80% of patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation, and virtually all patients receiving radiation therapy to the head and neck region.1 Gastrointestinal mucositis, manifesting predominantly as chemotherapy-induced diarrhea, affects 50–80% of patients receiving fluoropyrimidine- or irinotecan-based regimens. These complications cause significant pain, impair nutritional intake, increase infection risk, prolong hospitalization, escalate healthcare costs, and may necessitate treatment dose reductions, delays, or discontinuation — all of which can compromise tumor control and survival outcomes.2
Despite the magnitude of this problem, mucositis remains under-recognized and inconsistently managed across oncology practices. This guideline addresses the full spectrum of mucosal injury, from pathobiology and risk stratification through evidence-based prevention, assessment, and treatment, with the goal of standardizing care and improving patient outcomes.
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Pathobiology, Grading Scales, and Risk Factors | Five-phase pathobiology model (initiation, primary damage response, signal amplification, ulceration/infection, healing); WHO Oral Toxicity Scale; NCI CTCAE mucositis grading; Oral Mucositis Assessment Scale (OMAS); treatment-related risk factors (specific chemotherapy agents, radiation therapy fields and doses, conditioning regimens); patient-related risk factors; pre-treatment dental assessment |
| Part 2 | Oral Mucositis Prevention and Management | Oral cryotherapy (timing, duration, regimen-specific protocols); low-level laser therapy/photobiomodulation (parameters, evidence); palifermin (indications, dosing, timing); basic oral care protocols; agents with evidence against use; pain management (topical, systemic, PCA); nutritional support; infection management (candidiasis, HSV reactivation); assessment and monitoring; multidisciplinary team approach; patient education |
| Part 3 | GI Mucositis, Radiation-Induced Mucositis, and HSCT Considerations | GI mucositis pathophysiology and grading; chemotherapy-induced diarrhea prevention and management; loperamide protocol; octreotide for refractory diarrhea; irinotecan-specific diarrhea (early cholinergic vs. late secretory); immune checkpoint inhibitor colitis; head and neck radiation mucositis protocols; pelvic radiation enteritis/proctitis; combined chemoradiation considerations; TBI-related mucositis; palifermin in HSCT; engraftment syndrome |
Scope and Applicability: This guideline applies to all healthcare professionals involved in the care of adult cancer patients receiving cytotoxic chemotherapy, targeted therapy, immunotherapy, radiation therapy, or hematopoietic stem cell transplantation who are at risk for oral or gastrointestinal mucosal injury. It is relevant across inpatient, outpatient, and ambulatory oncology care settings.
Limitations: No guideline can anticipate all clinical situations. This document is not intended to replace individual clinical judgment by qualified professionals. Local institutional protocols, formulary availability, patient preferences, and individual clinical circumstances must always be considered in decision-making.
Elad S, Cheng KKF, Lalla RV, et al. “MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.” Cancer, 126(19): 4423–4431, 2020. Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). DOI: 10.1002/cncr.33100 ↩︎ ↩︎
Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J. “Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology, 26(suppl 5): v139–v151, 2015. European Society for Medical Oncology (ESMO). DOI: 10.1093/annonc/mdv202 ↩︎ ↩︎
Lalla RV, Bowen J, Barasch A, et al. “MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.” Cancer, 120(10): 1453–1461, 2014. DOI: 10.1002/cncr.28592 ↩︎
Worthington HV, Clarkson JE, Bryan G, et al. “Interventions for preventing oral mucositis for patients with cancer receiving treatment.” Cochrane Database of Systematic Reviews, 2011(4): CD000978. DOI: 10.1002/14651858.CD000978.pub5 ↩︎
Sonis ST. “The pathobiology of mucositis.” Nature Reviews Cancer, 4(4): 277–284, 2004. DOI: 10.1038/nrc1318 ↩︎
Rubenstein EB, Peterson DE, Schubert M, et al. “Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis.” Cancer, 100(S9): 2026–2046, 2004. DOI: 10.1002/cncr.20163 ↩︎
Benson AB, Ajani JA, Catalano RB, et al. “Recommended guidelines for the treatment of cancer treatment–induced diarrhea.” Journal of Clinical Oncology, 22(14): 2918–2926, 2004. DOI: 10.1200/JCO.2004.04.132 ↩︎
Chemotherapy-induced diarrhea management, irinotecan-specific protocols, immune checkpoint inhibitor colitis, head and neck radiation mucositis, pelvic radiation enteritis, chemoradiation, TBI-related mucositis, palifermin in HSCT, and engraftment syndrome.
Evidence-based oral mucositis prevention including cryotherapy, photobiomodulation, palifermin, and basic oral care; pain management; nutritional support; infection management; agents with evidence against use.
Five-phase pathobiology model of mucositis, comprehensive grading scales (WHO, NCI CTCAE, OMAS), treatment-related and patient-related risk factors, and pre-treatment dental assessment.